Buscar
Valneva SE
VALNAñadir a la lista de seguimiento
5.225USD
+0.135+2.65%
Cierre 07/02, 13:00（ET）Cotizaciones retrasadas 15 min
453.93MCap. mercado
PérdidaP/E TTM
Más Datos de Valneva SE Compañía
Valneva SE is a France-based company that specializes in the development, manufacture and commercialization of vaccines to protect people from infectious diseases through preventative medicine. The Company's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and DUKORAL, which is indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by Enterotoxigenic escherichia coli (ETEC). The Company has also vaccines in development, including candidates against Lyme disease, COVID-19 and chikungunya. Its technologies and services segment cooperates with various pharmaceutical companies using its platform: EB66 vaccine production cell line and IC31 adjuvant. The Company is focused on research and development (R&D) programs, as well as holds investment in product candidates and commercial products.
Información de Valneva SE
Símbolo de cotizaciónVALN
Nombre de la empresaValneva SE
Fecha de salida a bolsaJun 28, 2007
Director ejecutivoLingelbach (Thomas)
Número de empleados- -
Tipo de seguridadDepository Receipt
Fin del año fiscalJun 28
Dirección6, Rue Alain Bombard
CiudadSAINT-HERBLAIN
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísFrance
Código postal44800
Teléfono33228073710
Sitio Webhttps://valneva.com/
Símbolo de cotizaciónVALN
Fecha de salida a bolsaJun 28, 2007
Director ejecutivoLingelbach (Thomas)
Ejecutivos de Valneva SE
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Franck Grimaud
Mr. Franck Grimaud
Chief Business Officer
Chief Business Officer
--
--
Mr. James R. Sulat
Mr. James R. Sulat
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
--
--
Mr. Thomas Lingelbach
Mr. Thomas Lingelbach
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Anne-Marie Graffin
Ms. Anne-Marie Graffin
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Juan Carlos Jaramillo
Dr. Juan Carlos Jaramillo
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Vincent Dequenne
Mr. Vincent Dequenne
Chief Operating Officer
Chief Operating Officer
--
--
Mr. Peter Buehler
Mr. Peter Buehler
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Dipal Patel
Ms. Dipal Patel
Chief Commercial Officer
Chief Commercial Officer
--
--
Mr. James Connolly
Mr. James Connolly
Independent Director
Independent Director
--
--
Ms. Mailys Ferrere
Ms. Mailys Ferrere
Director, Representative of Bpifrance Participations SA
Director, Representative of Bpifrance Participations SA
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Franck Grimaud
Mr. Franck Grimaud
Chief Business Officer
Chief Business Officer
--
--
Mr. James R. Sulat
Mr. James R. Sulat
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
--
--
Mr. Thomas Lingelbach
Mr. Thomas Lingelbach
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Anne-Marie Graffin
Ms. Anne-Marie Graffin
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Juan Carlos Jaramillo
Dr. Juan Carlos Jaramillo
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Vincent Dequenne
Mr. Vincent Dequenne
Chief Operating Officer
Chief Operating Officer
--
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Valneva SE?
Los cinco principales accionistas de Valneva SE son: Mr. Franck Grimaud
¿Cuántas instituciones poseen acciones de Valneva SE (VALN)?
A fecha de 2026Q1, 36 instituciones poseen acciones de Valneva SE, con un valor de mercado combinado de aproximadamente 5.21M, lo que representa el 5.50% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -309162.00.
¿Cuál es la mayor fuente de ganancias de Valneva SE?
El 2026Q1, el segmento empresarial IXIARO generó la ganancia más alta para Valneva SE, ascendiendo a 98.42M y representando el 56.35% de la ganancia total.